Practically every day these weeks, new surveys and studies are being published about Belinostat. Today, a study regarding the effect of belinostat in International Journal of Gynecological Cancer titled:
Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian CancerConclusions: Belinostat, carboplatin, and paclitaxel combined was reasonably well tolerated and demonstrated clinical benefit in heavily-pretreated patients with EOC. The addition of belinostat to this platinum-based regimen represents a novel approach to EOC therapy and warrants further exploration.
